ADDED
As of January 24, 2026, there were 49,227,800 shares of the registrant s common stock outstanding, $0.01 par value per share.
In 2025, RMS accounted for 21.1% of our total revenue and approximately 4,140 of our employees, including approximately 190 science professionals with advanced degrees.
In 2025, our DSA segment represented 59.8% of our total revenue and employed approximately 11,760 of our employees including approximately 1,680 science professionals with advanced degrees.
In 2025, Manufacturing accounted for 19.1% of our total revenue and approximately 2,600 of our employees, including approximately 350 science professionals with advanced degrees.
In both cases - non-human primates we provide directly to clients and non-human primates which are utilized through our Safety Assessment services these large research models are sourced from Charles River internally or from Charles River audited and approved suppliers.
(Cambodia) Ltd., a Cambodia-based provider of non-human primates for regulatory required biomedical, pharmaceutical, and toxicological research purposes.
is now a part of the Company's DSA reporting segment for the purpose of being vertically integrated into DSA supply operations and the RMS reporting segment for those NHPs sold to third party customers.
Discovery services can streamline and enhance drug discovery programs for our clients, providing expertise and capabilities in all stages of discovery and all major modalities including small molecules, biologics, oligonucleotides, and cell and gene therapies.
In the discovery phase, we leverage our capabilities in pharmacokinetics, pharmacology, non-GLP toxicity assays, and predictive models to enable exposure and efficacy assessments, and the early identification and mitigation of potential safety issues to ensure a smooth progression into regulatory safety assessment.
For human pharmaceutical candidates, once a lead candidate is selected, toxicology studies are required to support clinical trials in humans and for 5 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
REMOVED
As of January 25, 2025, there were 51,141,607 shares of the registrant s common stock outstanding, $0.01 par value per share.
For example, we may use forward-looking statements when addressing topics such as: our expectations regarding the availability of non-human primates and our ability to diversify our non-human primate (NHP) supply chain; the outcome of (1) the U.S.
In 2024, RMS accounted for 20.5% of our total revenue and approximately 4,100 of our employees, including approximately 200 science professionals with advanced degrees.
In 2024, our DSA segment represented 60.5% of our total revenue and employed approximately 12,100 of our employees including approximately 1,500 science professionals with advanced degrees.
In 2024, Manufacturing accounted for 19.0% of our total revenue from continuing operations and approximately 2,800 of our employees, including approximately 380 science professionals with advanced degrees.
In both cases - non-human primates we provide directly to clients and non-human primates which are utilized through our Safety Assessment services these large research models are sourced from Charles River audited and approved suppliers, some of which we have an ownership and/or operational involvement.
This includes services to streamline and enhance drug discovery programs for our clients, including expertise and capabilities in all stages of discovery and all major modalities including small molecules, biologics (antibodies), oligonucleotides, and cell and gene therapies.
In the discovery phase, we leverage our capabilities in non-GLP toxicity assessment and predictive models to enable identification and mitigation of safety issues to ensure a smooth progression into regulatory safety assessment.
For human pharmaceutical candidates, once a lead candidate is selected, toxicology studies are required to support clinical trials in humans and for regulatory approval.
For new chemicals, industrial chemicals, agrochemicals, veterinary medicines, consumer products and medical devices, safety studies are performed to identify potential hazards to 5 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.